IntoCell, Inc.

Research IntoCell, Inc. (287840.KQ) on Bullrun: market cap KRW 223.68B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker287840.KQ
ExchangeKQ
CountrySouth Korea
SectorHealthcare
IndustryBiotechnology
CurrencyKRW
Market capKRW 223.68B
Financial periodQ2 2026
RevenueKRW 760.30M
Net income-KRW 2.07B
Free cash flow-KRW 2.99B
Gross margin100.0%

Valuation Snapshot

latest market cap is KRW 223.68B.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	KRW 223.68B	n/a	n/a	n/a

Dividend history

About IntoCell, Inc.

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers.

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ)

Frequently asked questions

What is IntoCell, Inc.'s market cap?

IntoCell, Inc.'s market capitalization is KRW 223.68B.